0001733413-18-000001.txt : 20180327 0001733413-18-000001.hdr.sgml : 20180327 20180327143509 ACCESSION NUMBER: 0001733413-18-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180327 DATE AS OF CHANGE: 20180327 EFFECTIVENESS DATE: 20180327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TFF Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001733413 IRS NUMBER: 824344737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-308663 FILM NUMBER: 18715055 BUSINESS ADDRESS: STREET 1: 2801 VIA FORTUNA, SUITE 425 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 737-802-1979 MAIL ADDRESS: STREET 1: 2801 VIA FORTUNA, SUITE 425 CITY: AUSTIN STATE: TX ZIP: 78746 D 1 primary_doc.xml X0708 D LIVE 0001733413 TFF Pharmaceuticals, Inc. 2801 VIA FORTUNA, SUITE 425 AUSTIN TX TEXAS 78746 737-802-1979 DELAWARE None None Corporation true 2018 Robert S. Mills, Jr. 2801 Via Fortuna, Suite 425 Austin TX TEXAS 78746 Executive Officer Director Brian Windsor 2801 Via Fortuna, Suite 425 Austin TX TEXAS 78746 Executive Officer Director Kirk Coleman 2801 Via Fortuna, Suite 425 Austin TX TEXAS 78746 Executive Officer Aaron Fletcher 2801 Via Fortuna, Suite 425 Austin TX TEXAS 78746 Director Pharmaceuticals Decline to Disclose 06b false 2018-03-13 false true false 10000 National Securities Corporation 7569 None None One Union Square 600 University Street, Suite 2900 Seattle WA WASHINGTON 98101 AZ ARIZONA AR ARKANSAS CA CALIFORNIA CO COLORADO CT CONNECTICUT DC DISTRICT OF COLUMBIA FL FLORIDA GA GEORGIA IL ILLINOIS IN INDIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA NV NEVADA NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OK OKLAHOMA PA PENNSYLVANIA TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON WI WISCONSIN false 14155000 14155000 0 false 224 1415500 0 Represents 10% of the gross proceeds. The placement agent also received a warrant to purchase 10% of the number of shares of Series A Preferred Stock issued in the offering. 0 false TFF Pharmaceuticals, Inc. /s/ Kirk Coleman Kirk Coleman Chief Financial Officer 2018-03-27